<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Chen R</submitter><funding>Key-Area Research and Development Program of Guangdong Province</funding><funding>Guangzhou Science and Technology Plan Projects</funding><funding>"14th Five-Year Plan" team-building projects of Guangdong Academy of Agricultural Sciences</funding><funding>Special fund for scientific innovation strategy-construction of high level Academy of Agriculture Science</funding><funding>Guangdong Basic and Applied Basic Research Foundation</funding><funding>Qingyuan Science and Technology Program</funding><funding>the Innovation Fund projects of Guangdong Key Laboratory of Tea Plant Resources Innovation and Utilization</funding><funding>Innovation Fund projects of Guangdong Academy of Agricultural Sciences</funding><pagination>3037</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9332116</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>14(15)</volume><pubmed_abstract>Liver injury is a significant public health issue nowadays. Shibi tea is a non-&lt;i>Camellia&lt;/i> tea prepared from the dried leaves of &lt;i>Adinandra nitida&lt;/i>, one of the plants with the greatest flavonoid concentration, with Camellianin A (CA) being the major flavonoid. Shibi tea is extensively used in food and medicine and has been found to provide a variety of health advantages. The benefits of Shibi tea and CA in preventing liver injury have not yet been investigated. The aim of this study was to investigate the hepatoprotective effects of extract of Shibi tea (EST) and CA in mice with carbon tetrachloride (CCl&lt;sub>4&lt;/sub>)-induced acute liver injury. Two different concentrations of EST and CA were given to model mice by gavage for 3 days. Treatment with two concentrations of EST and CA </pubmed_abstract><journal>Nutrients</journal><pubmed_title>Shibi Tea (&lt;i>Adinandra nitida&lt;/i>) and Camellianin A Alleviate CCl&lt;sub>4&lt;/sub>-Induced Liver Injury in C57BL-6J Mice by Attenuation of Oxidative Stress, Inflammation, and Apoptosis.</pubmed_title><pmcid>PMC9332116</pmcid><funding_grant_id>2020B0202080003</funding_grant_id><funding_grant_id>202126TD</funding_grant_id><funding_grant_id>2020A1515011266, 2021A1515010958</funding_grant_id><funding_grant_id>202102020047, 202002030202</funding_grant_id><funding_grant_id>DZXQY021</funding_grant_id><funding_grant_id>202115, 202035</funding_grant_id><funding_grant_id>2021CX02</funding_grant_id><funding_grant_id>R2019PY-JX004</funding_grant_id><pubmed_authors>Sun L</pubmed_authors><pubmed_authors>Lai X</pubmed_authors><pubmed_authors>Tang L</pubmed_authors><pubmed_authors>Yuan E</pubmed_authors><pubmed_authors>Zhu J</pubmed_authors><pubmed_authors>Zhang Z</pubmed_authors><pubmed_authors>Lian Y</pubmed_authors><pubmed_authors>Sun S</pubmed_authors><pubmed_authors>Wen S</pubmed_authors><pubmed_authors>Li Q</pubmed_authors><pubmed_authors>Xuan J</pubmed_authors><pubmed_authors>Chen R</pubmed_authors></additional><is_claimable>false</is_claimable><name>Shibi Tea (&lt;i>Adinandra nitida&lt;/i>) and Camellianin A Alleviate CCl&lt;sub>4&lt;/sub>-Induced Liver Injury in C57BL-6J Mice by Attenuation of Oxidative Stress, Inflammation, and Apoptosis.</name><description>Liver injury is a significant public health issue nowadays. Shibi tea is a non-&lt;i>Camellia&lt;/i> tea prepared from the dried leaves of &lt;i>Adinandra nitida&lt;/i>, one of the plants with the greatest flavonoid concentration, with Camellianin A (CA) being the major flavonoid. Shibi tea is extensively used in food and medicine and has been found to provide a variety of health advantages. The benefits of Shibi tea and CA in preventing liver injury have not yet been investigated. The aim of this study was to investigate the hepatoprotective effects of extract of Shibi tea (EST) and CA in mice with carbon tetrachloride (CCl&lt;sub>4&lt;/sub>)-induced acute liver injury. Two different concentrations of EST and CA were given to model mice by gavage for 3 days. Treatment with two concentrations of EST and CA </description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Jul</publication><modification>2025-04-19T17:48:22.016Z</modification><creation>2022-08-06T14:52:53.962Z</creation></dates><accession>S-EPMC9332116</accession><cross_references><pubmed>35893891</pubmed><doi>10.3390/nu14153037</doi></cross_references></HashMap>